Search

Author/Creator Basaran, Gul

1. Real-Life Analysis of Efficacy and Safety of Everolimus Plus Exemestane in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Patients: A Turkish Oncology Group (TOG) Study. (7th February 2022)

Authors:
Bilici, Ahmet; Uysal, Mukremin; Menekse, Serkan; Akin, Semih; Yildiz, Fatih; Turan, Merve; Sezgin Goksu, Sema; Beypinar, Ismail; Sakalar, Teoman; Değirmenci, Mustafa; Erdem, Dilek; Basaran, Gul; Olmez, Omer Fatih; Avci, Nilufer; Tural, Deniz; Sakin, Abdullah; Turker, Sema; Demir, Atakan; Temiz, S...
Journal:
Cancer investigation
Issue:
Volume 40:Number 2(2022)
Page Start:
199
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. A European Organisation for Research and Treatment of Cancer randomized, double-blind, placebo-controlled, multicentre phase II trial of anastrozole in combination with gefitinib or placebo in hormone receptor-positive advanced breast cancer (NCT00066378). (January 2016)

Authors:
Tryfonidis, Konstantinos; Basaran, Gul; Bogaerts, Jan; Debled, Marc; Dirix, Luc; Thery, Jean-Christophe; Tjan-Heijnen, Vivianne C.G.; Van den Weyngaert, Danielle; Cufer, Tanja; Piccart, Martine; Cameron, David
Journal:
European journal of cancer
Issue:
Volume 53(2016)
Page Start:
144
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗